Coeur Announces Second Quarter 2025 Earnings Call
Hosting the call will be Mitchell J. Krebs, Chairman, President and Chief Executive Officer of Coeur, who will be joined by Thomas S. Whelan, Senior Vice President and Chief Financial Officer, Michael 'Mick' Routledge, Senior Vice President and Chief Operating Officer, Aoife McGrath, Senior Vice President, Exploration, and other members of management. A replay of the call will be available through August 14, 2025.
Replay Numbers:
U.S.:
(877) 344-7529
Canada:
(855) 669-9658
International:
(412) 317-0088
Conference ID:
454 62 87
Expand
About Coeur
Coeur Mining, Inc. is a U.S.-based, well-diversified, growing precious metals producer with five wholly-owned operations: the Las Chispas silver-gold mine in Sonora, Mexico, the Palmarejo gold-silver complex in Chihuahua, Mexico, the Rochester silver-gold mine in Nevada, the Kensington gold mine in Alaska and the Wharf gold mine in South Dakota. In addition, the Company wholly-owns the Silvertip polymetallic critical minerals exploration project in British Columbia.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Eli Lilly (LLY) Partners with Superluminal for AI Drug Discovery
Eli Lilly and Company (NYSE:LLY) is one of the 9 Best NYSE Stocks to Buy According to Hedge Funds. On August 14, Reuters reported that Eli Lilly and Company (NYSE:LLY) has entered into a deal worth $1.3 billion with Superluminal Medicines, a privately held company. The aim of this deal is to use AI to discover and develop small-molecule drugs for obesity and other cardiometabolic diseases. As per the report by Reuters, Eli Lilly and Company (NYSE:LLY) is already leading the obesity treatment market, which is expected to be worth $150 billion by the next decade. The company is looking to solidify its foothold in this area by developing next-generation drugs, making acquisitions, and entering into partnerships. The deal allows Eli Lilly and Company (NYSE:LLY) to have exclusive rights to develop and commercialize drug candidates discovered with the help of Superluminal's proprietary AI-driven platform targeting G-protein-coupled receptors (GPCR). These proteins can influence physiological processes including metabolism, cell growth, and immune responses. Eli Lilly and Company (NYSE:LLY) is an American multinational pharmaceutical company focused on discovering, developing, and delivering innovative medicines. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Revenue Growth Stocks to Buy Now and 14 Best Aggressive Growth Stocks to Buy According to Analysts. Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
29 minutes ago
- Business Insider
New Buy Rating for Block (XYZ), the Technology Giant
Evercore ISI analyst Adam Frisch maintained a Buy rating on Block yesterday and set a price target of $96.00. The company's shares closed yesterday at $74.30. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Frisch covers the Technology sector, focusing on stocks such as Block, Shift4 Payments, and Toast Inc. According to TipRanks, Frisch has an average return of 36.0% and a 100.00% success rate on recommended stocks. In addition to Evercore ISI, Block also received a Buy from TR | OpenAI – 4o's Elisa Scalantra in a report issued yesterday. However, on August 14, Compass Point maintained a Sell rating on Block (NYSE: XYZ). Based on Block's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $6.05 billion and a net profit of $538.46 million. In comparison, last year the company earned a revenue of $6.16 billion and had a net profit of $195.27 million Based on the recent corporate insider activity of 114 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of XYZ in relation to earlier this year. Last month, Owen Britton Jennings, the Business Lead of XYZ sold 1,050.00 shares for a total of $72,723.00.
Yahoo
33 minutes ago
- Yahoo
SQM net profit slumps nearly 60% in Q2 on falling lithium prices
-- Chile's SQM (NYSE:SQM) reported a steep drop in profit for the second quarter as weaker lithium prices weighed on results. The world's second-largest lithium producer's net profit fell 59% to $88.4 million, well below analysts' expectations of $143.01 million, according to LSEG data. Revenue came in at $1.04 billion, roughly in line with the $1.064 billion forecast. The company said lithium prices declined about 34% from a year earlier. SQM's gross profit in Q2 fell 34% to $253.6 million from $383.9 million in the year-ago period. 'As anticipated, during the second quarter, we navigated a period of lower lithium market prices than those observed in previous quarters. In this context, some of the contracts we had in place, hit the lower limits set in those contracts, affecting the volumes agreed," CEO Ricardo Ramos said in the release. For the first six months of the year, the miner reported net income of $226 million, compared with a loss of $655.9 million a year earlier. Revenue fell 12.6% to $2.08 billion from $2.38 billion in the same period of 2024. Related articles SQM net profit slumps nearly 60% in Q2 on falling lithium prices After soaring 149%, this stock is back in our AI's favor - & already +25% in July 7 Undervalued Stocks on the Rise With 50%+ Upside Potential
